How to boost enrollment of Black, Hispanic patients in pediatric clinical trials

by UT Southwestern Medical Center

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

While Black and Hispanic families are enthusiastic about research participation, other provider- and system-focused factors may influence their involvement in pediatric oncology clinical trials, a UT Southwestern Medical Center-led study found. The findings, published in JAMA Network Open, focused on parent and clinician perspectives, revealing opportunities to increase clinical trial participation among historically marginalized patients to help improve outcomes and make trial results more generalizable.

"This is one of the first studies to center on the perspectives of Black and Hispanic families regarding research participation," said the study's lead author, Puja Umaretiya, M.D., M.S., assistant professor of pediatrics and a member of the Population Science and Cancer Control Research Program in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern.

"Our findings highlight that historically marginalized parents are very willing to participate in clinical trials, if offered. Efforts to reduce clinician gatekeeping—where doctors decide not to offer clinical trials based on assumptions—and address material hardship are needed to improve equitable participation."

Persistent gaps in trial access

While survival rates for children with cancer have improved from 10% to 85% over the past 75 years, research suggests disparities persist, with Black and Hispanic children continuing to have lower survival rates than white children.

Efforts to address these gaps include increasing participation in clinical trials, which provide access to new therapies and help ensure findings apply broadly across patient populations. However, a 2024 study by the U.S. Department of Health and Human Services that sampled clinical trials found that most missed enrollment targets for underrepresented groups.

Despite the importance of clinical trial participation, there are limited data on the perspectives of Black and Hispanic families regarding involvement. To better understand these views, researchers surveyed 60 parents of Black and Hispanic children with cancer and 15 clinicians from Dana-Farber Cancer Institute. About 73% of participating families reported experiencing household material hardship, including food, housing, transportation or utility insecurity.

Trust is high, materials are not

Using surveys from all participants and interviews with a subset of 20 participating parents and the 15 clinicians, researchers identified factors that facilitated clinical trial participation as well as those that acted as barriers.

Two key factors that both parents and clinicians identified as facilitators of participation were altruism and trustworthiness. Notably, a majority of parents reported very high levels of trust in their oncology team. When it came to barriers to participation, parents and clinicians cited the informed consent discussion required for trial participation and difficult-to-understand trial materials. They noted these factors were particularly challenging for families who did not speak English.

While clinicians perceived issues related to household material hardship and the experimental nature of clinical trials as barriers to family participation, parents did not identify these as drivers in their decision-making, highlighting a discrepancy between parent-clinician perceptions. Clinicians also identified gatekeeping related to willingness to engage families and adherence to trial requirements amid financial hardship as potential barriers.

"Equitable clinical trial participation is important because it ensures that our research is generalizable, identifies mechanisms that may drive worse outcomes for certain populations, and improves the trustworthiness of the medical system. There is more we can do to support participation by marginalized families, such as ensuring that we are offering trials to all families and supporting them with the resources needed to successfully participate," Umaretiya said.

Publication details

Puja J. Umaretiya et al, Pediatric Oncology Clinical Trial Participation Among Families From Historically Marginalized Groups, JAMA Network Open (2026). DOI: 10.1001/jamanetworkopen.2026.26538

Journal information: JAMA Network Open

Clinical categories

PediatricsOncologyChildren's health Provided by UT Southwestern Medical Center Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: How to boost enrollment of Black, Hispanic patients in pediatric clinical trials (2026, August 3) retrieved 3 August 2026 from https://medicalxpress.com/news/2026-08-boost-enrollment-black-hispanic-patients.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.